The Hepatitis C treatment Ledipasvir/sofosbuvir was approved by the FDA in 2015 as a once-daily regimen for the treatment of HCV. The treatment, though proven effective in controlled trials, lacked data on how well it worked in the real-world.
Researchers from UMass Medical School's Clinical Pharmacy Services and Center for Health Policy and Research tested Ledipasvir/sofosbuvir to identify predictors of treatment failure in a Massachusetts Medicaid population. They did so by carrying out a retrospective cohort study which evaluated treatment rates within a Medicaid population of 796 Primary Care Clinician and fee-for-service plan members. They found the treatment was largely successful in creating a sustained viral response, which was achieved in 95% of members.